Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Buys 2,600 Shares of Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) insider Nishant Saxena bought 2,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were acquired at an average cost of $9.63 per share, with a total value of $25,038.00. Following the transaction, the insider owned 77,900 shares in the company, valued at approximately $750,177. This represents a 3.45% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Corbus Pharmaceuticals Price Performance

CRBP stock traded up $0.25 during midday trading on Wednesday, reaching $9.76. 548,769 shares of the company’s stock traded hands, compared to its average volume of 329,271. The company has a market capitalization of $182.22 million, a P/E ratio of -1.58 and a beta of 2.59. Corbus Pharmaceuticals Holdings, Inc. has a fifty-two week low of $7.12 and a fifty-two week high of $20.56. The business has a 50-day moving average price of $8.79 and a two-hundred day moving average price of $9.06.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.55). As a group, research analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -5.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRBP has been the subject of several recent research reports. Wall Street Zen downgraded Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Guggenheim reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals in a research report on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Friday, July 17th. Wedbush reduced their price target on Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 27th. Finally, Mizuho decreased their price target on Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating for the company in a report on Tuesday, June 23rd. Eight analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Corbus Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $41.12.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Persistent Asset Partners Ltd bought a new stake in shares of Corbus Pharmaceuticals in the 4th quarter worth about $54,000. Virtu Financial LLC bought a new position in shares of Corbus Pharmaceuticals during the fourth quarter worth about $88,000. Barclays PLC lifted its position in shares of Corbus Pharmaceuticals by 280.0% during the fourth quarter. Barclays PLC now owns 14,758 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 10,874 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in Corbus Pharmaceuticals in the third quarter worth about $129,000. Finally, Bank of America Corp DE grew its stake in Corbus Pharmaceuticals by 53,592.3% in the first quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 13,934 shares in the last quarter. 64.64% of the stock is owned by institutional investors and hedge funds.

Corbus Pharmaceuticals News Roundup

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target for Corbus Pharmaceuticals, well above recent trading levels. The firm’s institutional ownership is also substantial, with several hedge funds increasing their positions, which may provide support for the stock. Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals Stock
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the data also shows an invalid “NaN” percentage change, it offers little meaningful insight into current trading pressure.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including estimates of losses of $6.11 per share for 2026, $6.83 for 2027, $5.56 for 2028 and $2.07 for 2029. Its 2030 forecast was cut sharply to $0.15 from $1.29, indicating a slower path to profitability. HC Wainwright Estimate Changes for Corbus Pharmaceuticals
• Negative Sentiment: Company insiders sold shares: CEO Yuval Cohen sold 17,000 shares and CFO Sean Moran sold 12,000 shares at an average price of $10.08. Although both executives retained sizable holdings, the sales reduce their positions by approximately 9.75% and 12.41%, respectively, potentially weighing on sentiment. Corbus Pharmaceuticals CFO SEC Filing
• Negative Sentiment: Corbus recently reported a quarterly loss of $1.81 per share, missing the $1.26 consensus estimate by $0.55. The clinical-stage company’s high beta and lack of current earnings leave CRBP particularly sensitive to clinical, financing and forecast-related news.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.